骨氏葆方治疗肾虚血瘀型膝重度骨关节炎的临床研究

目的?观察骨氏葆方治疗肾虚血瘀型膝重度骨关节炎的临床疗效及安全性。方法?选取70例肾虚血瘀型膝重度骨关节炎患者为研究对象，其中治疗组38例和对照组32例，2组患者均给予健康教育和膝关节内粘疗法等基础治疗，对照组予盐酸氨基葡萄糖胶囊口服，治疗组予骨氏葆方口服，共治疗5周。在治疗前后采用骨关节炎指数量表（WOMAC）及膝骨关节炎严重程度指数量表（ISOA）评价患者治疗效果，采用中医症状评分标准对患者的临床症状进行评分，并监测治疗前后患者血沉、降钙素（CT）及骨型碱性磷酸酶（BALP）的变化情况。结果?与治疗前比较，2组患者血沉明显下降（P＜0.01），治疗组低于对照组（P<0.05），降钙素及骨型碱性磷酸酶无显著变化（P＞0.05）；2组患者症状、体征积分均显著下降(P<0.01)，治疗组下降程度显著大于对照组（P＜0.01）；2组患者疼痛评分、WOMAC评分及ISOA评分均明显降低（P＜0.01），治疗组低于对照组（P＜0.01）；治疗组总有效率为97.37%，显著高于对照组总有效率(80.00%)，P＜0.05。2组患者在治疗过程中均无出现明显不良反应。结论?骨氏葆方可降低肾虚血瘀型膝重度骨关节炎患者的血沉，能够有效改善患者临床症状。 

Clinical Research of Gushibao Pill on Severe Kidney Circulation Deficiency and Blood Stasis Type Knee Osteoarthritis

OBJECTIVE?To observe the clinical effect and safety of treatment of Gushibao pill on severe kidney circulation deficiency and blood stasis type knee osteoarthritis. METHODS?70 patients with severe knee osteoarthritis were selected for this study， and were divided into the treatment group (38 cases) and the control group (32 cases). Patients of two groups were given health education and basic knee stick therapy treatment. On the basis of basic treatment， patients in the control group were given glucosamine hydrochloride capsules orally and treatment group were give Gubaoshi pill. WOMAC Osteoarthritis Index Scale and ISOA knee osteoarthritis severity index scale were used to evaluate the outcomes of two groups. Chinese medicine symptom score were used to evaluate the clinical symptoms. ESR， calcitonin (CT) and bone alkaline phosphatase (BALP) were detected before and after treatment. RESULTS?Erythrocyte sedimentation rate in the control group significantly decreased after a course of treatment (P<0.05)， and bone alkaline phosphatase and calcitonin showed no significant change(P>0.05). Erythrocyte sedimentation rate decreased significantly in treatment group after treatment (P<0.05)， and bone alkaline phosphatase and calcitonin showed no significant change (P>0.05). Scored of symptoms and signs significantly decreased in two groups， and the decreased extent of treatment group was significantly greater than that of the control group (P<0.05). Pain score， WOMAC score and ISOA scores were significantly lower in two groups of patients compared with the condition before treatment (P<0.05). After treatment， pain score， WOMAC score and ISOA scores of treatment group were lower than those of the control group (P<0.05). The total effective rate of treatment group was 97.37%， and was significantly higher than the control group (80.00%). The difference was statistically significant (P<0.05). Two patients had no obvious adverse reactions during treatment. CONCLUSION?Gushibao pill can decrease the level of erythrocyte sedimentation rate in patients with severe kidney circulation deficiency and blood stasis knee osteoarthritis. It is effective and safe.